



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/040,010	01/04/2002	Thomas M. Mills	M0351-267875	8818

7590 08/26/2003

Cynthia B. Rothschild, Esq.  
Kilpatrick Stockton LLP  
1001 W. 4th Street  
Winston-Salem, NC 27101

EXAMINER

BAHAR, MOJDEH

ART UNIT

PAPER NUMBER

1617

DATE MAILED: 08/26/2003

9

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	10/040,010	MILLS ET AL.
	Examiner	Art Unit
	Mojdeh Bahar	1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

1) Responsive to communication(s) filed on 21 April 2003.

2a) This action is **FINAL**.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

4) Claim(s) 1-50 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) \_\_\_\_\_ is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) 1-50 are subject to restriction and/or election requirement.

**Application Papers**

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some \* c) None of:  
1. Certified copies of the priority documents have been received.  
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

1) Notice of References Cited (PTO-892)      4) Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_.  
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)      5) Notice of Informal Patent Application (PTO-152)  
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_.      6) Other:

## DETAILED ACTION

Applicant's response filed April 21, 2003 is acknowledged.

Upon reconsideration, the outstanding restriction requirement is withdrawn and the new restriction requirement is set forth below.

### *Election/Restrictions*

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-20 and 22-25, drawn to a method of treating sexual dysfunction by employing compounds which attenuates RhoA and/or Rho-kinase activity, classified in class 514, subclass 1+.
- II. Claim 21, drawn to drawn to a method of treating sexual dysfunction by employing compounds which attenuates RhoA and/or Rho-kinase activity and gene therapy, classified in class 514, subclass 1+, classified in class 435, subclass 69.1+, 440+, and 320+.
- III. Claim 26, drawn to a method of treating priapism, classified in class 514, subclass 1+.
- IV. Claims 27-50, drawn to a composition, classified in class 424, subclass 401+.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In

the instant case the different inventions have different modes of operation. The invention of Group II employs gene therapy; while the invention of Group I does not. It is well recognized that method of gene therapy is patentably distinct from the method utilizing conventional medicine as they are classified into different classification.

Inventions I and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different function. The invention of Group I functions to treat male or female sexual dysfunction and the invention of Group II functions to treat priapism. One of the goals of treatment of male sexual dysfunction is to induce penile erection; while that of priapism is the opposite, i.e., reduce or abort penile erection.

Inventions IV and I-III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the method of treating male or female sexual dysfunction can be practiced with materially different product such as PGE1. The method of treating priapism can be practiced with materially different product such as vasoconstricting agents.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Claims 7, 9-12, 33, and 35-38 are generic to a plurality of disclosed patentably distinct species comprising compounds that “reduces that amount of active Rho-kinase enzyme”, “inhibits binding of GTP to RhoA enzyme”, and “inhibit translocation of RhoA enzyme to the cellular membrane” and “acts on downstream target of Rho-kinase”; as well as compounds that potentiates the effects of nitric oxide”. Applicant is required under 35 U.S.C. 121 to elect a single disclosed compound for each functions recited in the claims 7, 9-12, 33, and 35-38 if the invention of Group I, II, and IV are elected, even though this requirement is traversed. For example, applicant is required to elect one compound for reducing that amount of active Rho-kinase enzyme, one compound for inhibiting binding of GTP to RhoA enzyme, one for inhibits binding of GTP to RhoA enzyme, one for inhibit translocation of RhoA enzyme to the cellular membrane, and one for acts on downstream target of Rho-kinase”; as well as compounds that potentiates the effects of nitric oxide.

Moreover, if group II is elected, applicant is required to elect a single disclosed species of target protein that the gene therapy is affected, even though this requirement is traversed. All the target proteins in the pathway in Fig. 2 of the specification are patentably distinct target for gene therapy. Searching for all the compounds and proteins recited herein would impose as undue burden to the Office.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because the above restriction/election requirement is complex, a telephone call to applicant's agent to request an oral election was not made. See M.P.E.P. Sec. 812.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mojdeh Bahar whose telephone number is (703) 305-1007. The examiner can normally be reached on Mon - Fri from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (703) 305-1877. The fax

Art Unit: 1617

phone number for the organization where this application or proceeding is assigned is  
(703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Mojdeh Bahar  
August 22, 2003

  
\_\_\_\_\_  
SREENI PADMANABHAN  
PRIMARY EXAMINER  
8/25/05